Opus Genetics, Inc. Basic Shares Outstanding (Weighted Average)
Opus Genetics, Inc. (IRD) reported Basic Shares Outstanding (Weighted Average) of 95.48 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 95.48M shares, a 50.66% increase year-over-year.
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 86.89M shares, a 156.43% increase year-over-year.
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 80.59M shares, a 165.44% increase year-over-year.
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 70.64M shares, a 170.17% increase year-over-year.
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 62.22M shares, a 132.91% increase from fiscal 2024.
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 26.72M shares, a 23.74% increase from fiscal 2023.
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 21.59M shares, a 8.32% increase from fiscal 2022.
- Opus Genetics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 19.93M shares, a 34.19% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 95.48M shares 10-Q · filed 2026-08-06 | 91.21M shares 10-Q · filed 2026-08-06 | 87.65M shares derived: average of 3 quarters · filed 2026-08-06 | 83.40M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 86.89M shares 10-Q · filed 2026-05-12 | 83.74M shares derived: average of 2 quarters · filed 2026-05-12 | 79.37M shares derived: average of 3 quarters · filed 2026-05-12 | 75.37M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 80.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 75.61M shares derived: average of 2 quarters · filed 2026-03-12 | 71.53M shares derived: average of 3 quarters · filed 2026-08-06 | 62.22M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 70.64M shares 10-Q · filed 2025-11-12 | 67.01M shares derived: average of 2 quarters · filed 2026-08-06 | 56.10M shares 10-Q · filed 2025-11-12 | 49.56M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 63.38M shares 10-Q · filed 2026-08-06 | 48.71M shares 10-Q · filed 2026-08-06 | 42.54M shares derived: average of 3 quarters · filed 2026-08-06 | 38.44M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 33.88M shares 10-Q · filed 2026-05-12 | 32.12M shares derived: average of 2 quarters · filed 2026-05-12 | 30.13M shares derived: average of 3 quarters · filed 2026-05-12 | 29.05M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 30.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 28.25M shares derived: average of 2 quarters · filed 2026-03-12 | 27.44M shares derived: average of 3 quarters · filed 2026-03-12 | 26.72M shares 10-K · filed 2026-03-12 |
| 2024-09-30 | 26.15M shares 10-Q · filed 2025-11-12 | 25.99M shares derived: average of 2 quarters · filed 2025-11-12 | 25.50M shares 10-Q · filed 2025-11-12 | 24.88M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 25.83M shares 10-Q · filed 2025-08-13 | 25.18M shares 10-Q · filed 2025-08-13 | 24.45M shares derived: average of 3 quarters · filed 2025-08-13 | 23.70M shares derived: average of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | 24.52M shares 10-Q · filed 2025-05-15 | 23.76M shares derived: average of 2 quarters · filed 2025-05-15 | 22.99M shares derived: average of 3 quarters · filed 2025-05-15 | 22.48M shares derived: average of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | 23.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 22.23M shares derived: average of 2 quarters · filed 2025-03-31 | 21.80M shares derived: average of 3 quarters · filed 2025-03-31 | 21.59M shares 10-K · filed 2025-03-31 |
| 2023-09-30 | 21.45M shares 10-Q · filed 2024-11-12 | 21.20M shares derived: average of 2 quarters · filed 2024-11-12 | 21.12M shares 10-Q · filed 2024-11-12 | 21.04M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 20.96M shares 10-Q · filed 2024-08-13 | 20.95M shares 10-Q · filed 2024-08-13 | 20.91M shares derived: average of 3 quarters · filed 2024-08-13 | 20.80M shares derived: average of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | 20.94M shares 10-Q · filed 2024-05-10 | 20.88M shares derived: average of 2 quarters · filed 2024-05-10 | 20.75M shares derived: average of 3 quarters · filed 2024-05-10 | 20.44M shares derived: average of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | 20.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 20.66M shares derived: average of 2 quarters · filed 2024-03-08 | 20.27M shares derived: average of 3 quarters · filed 2024-03-08 | 19.93M shares 10-K · filed 2024-03-08 |
| 2022-09-30 | 20.50M shares 10-Q · filed 2023-11-13 | 20.00M shares derived: average of 2 quarters · filed 2023-11-13 | 19.64M shares 10-Q · filed 2023-11-13 | 19.19M shares derived: average of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | 19.50M shares 10-Q · filed 2023-08-11 | 19.20M shares 10-Q · filed 2023-08-11 | 18.76M shares derived: average of 3 quarters · filed 2023-08-11 | 18.30M shares derived: average of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | 18.89M shares 10-Q · filed 2023-05-15 | 18.39M shares derived: average of 2 quarters · filed 2023-05-15 | 17.90M shares derived: average of 3 quarters · filed 2023-05-15 | 16.83M shares derived: average of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | 17.89M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 17.41M shares derived: average of 2 quarters · filed 2023-03-30 | 16.14M shares derived: average of 3 quarters · filed 2023-03-30 | 14.85M shares 10-K · filed 2023-03-30 |
| 2021-09-30 | 16.93M shares 10-Q · filed 2022-11-04 | 15.27M shares derived: average of 2 quarters · filed 2022-11-04 | 13.84M shares 10-Q · filed 2022-11-04 | 12.27M shares derived: average of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | 13.61M shares 10-Q · filed 2022-08-12 | 12.27M shares 10-Q · filed 2022-08-12 | 10.71M shares derived: average of 3 quarters · filed 2022-08-12 | 8.97M shares derived: average of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | 10.92M shares 10-Q · filed 2022-05-13 | 9.27M shares derived: average of 2 quarters · filed 2022-05-13 | 7.43M shares derived: average of 3 quarters · filed 2022-05-13 | 6.50M shares derived: average of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | 7.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | 5.68M shares derived: average of 2 quarters · filed 2022-03-24 | 5.03M shares derived: average of 3 quarters · filed 2022-03-24 | 4.66M shares 10-K · filed 2022-03-24 |
| 2020-09-30 | 3.74M shares 10-Q · filed 2021-11-12 | 3.74M shares derived: average of 2 quarters · filed 2021-11-12 | 3.68M shares 10-Q · filed 2021-11-12 | |
| 2020-06-30 | 3.74M shares 10-Q · filed 2021-08-12 | 3.65M shares 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | 3.55M shares 10-Q · filed 2021-05-07 | |||
| 2018-06-30 | 31.74M shares 10-Q · filed 2018-08-03 | 31.74M shares 10-Q · filed 2018-08-03 | ||
| 2017-06-30 | 26.00M shares 10-Q · filed 2018-08-03 | 24.93M shares 10-Q · filed 2018-08-03 | ||
| 2016-06-30 | 21.32M shares 10-Q · filed 2017-08-04 | 20.79M shares 10-Q · filed 2017-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |